P70 S6 KINASE INHIBITOR AND EGFR INHIBITOR COMBINATION THERAPY

摘要

The present invention provides a combination therapy comprising the compound 4-[4-[4-(4-fluoro-3-trifluoromethylphenyl)-1-methyl-1H-imidazol-2-yl]piperidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor which is erlotinib hydrochloride for simultaneous, separate or sequential use in therapy and a method for use in the treatment of glioblastoma multiforme, adenocarcinomas of the colon, non-small-cell lung cancer, small-cell lung cancer, cisplatin-resistant small-cell lung cancer, ovarian cancer, leukemia, pancreatic cancer, prostate cancer, mammary carcinoma, renal cell carcimoma, multiple myeloma, Kaposis Sarcoma, Hodgkins lymphoma, lymphangioleiomyomatosis, Non-Hodgkins lymphoma or sarcoma.